| 摘要 |
The present invention relates to a pharmaceutical composition for preventing and treating kidney disorders caused by osmotic stress, containing an inhibitor for the phosphorylation of TAZ tyrosine as an active ingredient. More specifically, it has been ascertained that TAZ inhibits the activity of NFAT5/TonEBP, the activity of c-Abl is required for the interaction between TAZ and NFAT5/TonEBP, phosphorylated TAZ inhibits the binding activity of NFAT5/TonEBP, and the inhibition of TAZ maximizes the expression of a target gene and the activity of NFAT5/TonEBP for relieving the influence of a hypertonic stimulus under in vivo hypertonic conditions caused by dehydration, and thus the inhibitor for phosphorylation of TAZ tyrosine can be useful for preventing or treating kidney disorders caused by osmotic stress. |
